Vectorite Biomedical Inc. (TPEX:4170)
12.45
+0.25 (2.05%)
Sep 15, 2026, 2:00 PM CST
Vectorite Biomedical Revenue
Vectorite Biomedical had revenue of 27.13M TWD in the half year ending June 30, 2026, with 14.95% growth. This brings the company's revenue in the last twelve months to 54.81M, down -19.28% year-over-year. In the year 2025, Vectorite Biomedical had annual revenue of 61.41M with 6.29% growth.
Revenue (ttm)
54.81M
Revenue Growth
-19.28%
P/S Ratio
1.40
Revenue / Employee
n/a
Employees
n/a
Market Cap
76.56M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.41M | 3.64M | 6.29% |
| Dec 31, 2024 | 57.77M | 1.92M | 3.43% |
| Dec 31, 2023 | 55.85M | 12.94M | 30.15% |
| Dec 31, 2022 | 42.91M | 14.14M | 49.16% |
| Dec 31, 2021 | 28.77M | 4.23M | 17.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioLASCO Taiwan | 258.04M |
| RBC Bioscience | 220.60M |
| Visgeneer | 170.72M |
| Lukas Biomedical | 170.01M |
| Feng Chi Biotech | 156.99M |
| Enimmune | 53.45M |
| Neith | 31.84M |
| SynCore Biotechnology Co.,Ltd | 26.24M |